Tonix Pharmaceuticals Holding Corp (OQ:TNXP)

Mar 24, 2020 05:15 pm ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the quarter and year ended December 31, 2019, and provided an overview of recent...
Mar 23, 2020 04:30 pm ET
Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting a virtual presentation in conjunction with the Spring Investor...
Mar 20, 2020 09:31 am ET
Thinking about buying stock in Gilead Sciences, Petmed Express, Tilray, Tonix Pharmaceuticals, or Wix.Com?
NEW YORK, March 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GILD, PETS, TLRY, TNXP, and WIX....
Mar 03, 2020 05:00 pm ET
Tonix Pharmaceuticals Holding Corp. Closes $16,005,000 Common Stock Registered Direct Offering
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced registered direct offering, with gross proceeds of $16,005,000 before...
Feb 28, 2020 08:45 am ET
Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market
TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of...
Feb 26, 2020 07:00 am ET
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-180
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today a strategic collaboration with Southern Research to support the development of a vaccine, TNX-1800* (live...
Feb 11, 2020 04:01 pm ET
Tonix Pharmaceuticals Announces Closing of $7.5 million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering with total gross proceeds of approximately...
Feb 07, 2020 08:45 am ET
Tonix Pharmaceuticals Prices $7.5 million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $7.5 million before...
Feb 05, 2020 05:15 pm ET
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 RECOVERY Study of Tonmya® (TNX-102 SL) in PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that the Company has decided to stop enrollment in the Phase 3 RECOVERY study of Tonmya# or TNX-102 SL*...
Feb 04, 2020 07:00 am ET
Tonix Pharmaceuticals to Participate in Upcoming February Investor Conferences
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate in three upcoming investor conferences. Details of the Tonix presentations and webcasts are as follows: Event:BIO...
Jan 29, 2020 04:15 pm ET
Tonix Pharmaceuticals Presented Results from a Preclinical Study of TNX-801, a Potential Vaccine to Prevent Smallpox and Monkeypox, in a Poster Presentation at the 2020 American Society for Microbiolo
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, presented preclinical results of TNX-801 (live virus vaccine for percutaneous administration) to potentially prevent smallpox and...
Jan 24, 2020 07:00 am ET
Tonix Pharmaceuticals Announces Successful Completion of a Fed-Fasting and Dose Proportionality Study of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company, today announced that it has completed the required fed-fasting and dose proportionality tests of TNX-102 SL in healthy volunteers to support the...
Jan 23, 2020 07:00 am ET
Tonix Pharmaceuticals to Present Results from Preclinical Study of TNX-801 in a Poster Presentation at the 2020 American Society for Microbiology (ASM) Biothreats Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical results of TNX-801 in a poster at the 2020 ASM Biothreats Conference. The...
Jan 07, 2020 07:00 am ET
Tonix Pharmaceuticals to Present at Biotech Showcase 2020
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and conduct investor meetings at Biotech Showcase 2020 being held...
Dec 16, 2019 03:15 pm ET
Tonix Pharmaceuticals Announces Plan to Develop TNX-601 CR Tablets for Once-Daily Treatment of Major Depressive Disorder, in Addition to PTSD, After Successful Completion of Phase 1 Pharmacokinetic St
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has developed a controlled release formulation of tianeptine oxalate, TNX-601 CR (tianeptine oxalate...
Dec 11, 2019 04:05 pm ET
Tonix Pharmaceuticals Announces New European Patent for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office ("EPO") issued European Patent No. 2968992 to the Company on December 11, 2019....
Dec 10, 2019 07:00 am ET
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304). RELIEF is a potential pivotal...
Dec 04, 2019 07:00 am ET
Tonix Pharmaceuticals to Present at 12th Annual LD Micro Main Event
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being held December 10-12, 2019, in Bel-Air, Calif. Details of the Tonix...
Dec 03, 2019 07:00 am ET
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global...
Nov 26, 2019 04:05 pm ET
Tonix Pharmaceuticals Announces Receipt of FDA Official Minutes from Breakthrough Therapy Type B Clinical Guidance Meeting for Tonmya® as a Potential New Treatment for PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it received the official minutes from the Breakthrough Therapy Type B Clinical Guidance meeting with the...
Nov 25, 2019 04:05 pm ET
Tonix Pharmaceuticals to Participate in Benchmark’s Annual Discovery 1x1 Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will be conducting investor meetings at Benchmark’s 8th Annual Discovery 1x1...
Nov 21, 2019 08:00 am ET
Tonix Pharmaceuticals Announces Initiation of the Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that, having successfully closed an underwritten public equity offering for $9.0 million, it has initiated the...
Nov 20, 2019 04:05 pm ET
Tonix Pharmaceuticals Completes Pre-IND Meeting with FDA for TNX-102 SL as a Clinical Candidate for Alcohol Use Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has received the official meeting minutes from a recent Type B pre-IND meeting with the U.S. Food and Drug...
Nov 20, 2019 07:00 am ET
Tonix Pharmaceuticals Announces Closing of $9.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering with total gross proceeds of approximately...
Nov 15, 2019 08:30 am ET
Tonix Pharmaceuticals Prices $9.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $9.0 million before...
Nov 08, 2019 04:45 pm ET
Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September 30, 2019, and provided an overview of recent operational...
Nov 04, 2019 07:00 am ET
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that in the currently-enrolling Phase 3 study of Tonmya®* (or TNX-102 SL, cyclobenzaprine sublingual tablets, 5.6...
Oct 31, 2019 01:00 pm ET
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for...
Oct 23, 2019 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,449,203 to the Company on October...
Oct 15, 2019 07:00 am ET
Tonix Pharmaceuticals Joins the Alliance for Biosecurity
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for Biosecurity (the Alliance). The Alliance is a coalition of biopharmaceutical...
Oct 07, 2019 07:00 am ET
Tonix Pharmaceuticals Announces that the European Patent Office Opposition Division Has Upheld Its Patent for the Use of the Active Ingredient in TNX-102 SL, Cyclobenzaprine, for the Treatment of PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office’s (EPO) Opposition Division has upheld the Company's European Patent 2501234B1...
Oct 03, 2019 08:00 am ET
Tonix Pharmaceuticals Announces Completion of Long-Term Exposure Studies in Participants with PTSD to Evaluate the Tolerability of TNX-102 SL 5.6 mg
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced Tonix has completed collecting the required long-term safety exposure data of TNX-102 SL 5.6 mg in participants...
Sep 16, 2019 04:15 pm ET
Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreati
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has obtained an exclusive license from Columbia University for the development of TNX-1700 (rTFF2) for...
Sep 16, 2019 07:00 am ET
Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled “D-578, an orally active triple monoamine reuptake inhibitor, displays...
Sep 12, 2019 07:00 am ET
Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the 2019 annual National Association of Veterans’ Research and...
Sep 10, 2019 07:00 am ET
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences. Details of the Tonix Pharmaceuticals presentations and webcasts are as...
Sep 04, 2019 07:00 am ET
Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase 1 study evaluating the safety, tolerability and pharmacokinetics (PK) of...
Aug 21, 2019 07:00 am ET
Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Preventio
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital...
Aug 20, 2019 07:00 am ET
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an exclusive agreement to in-license a triple reuptake inhibitor (TRI), TNX-1600 (formerly D-578), to treat...
Aug 12, 2019 08:00 am ET
Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended June 30, 2019, and an overview of recent operational highlights. Tonix’s...
Aug 02, 2019 04:05 pm ET
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Patrick Grace stepped down from the Company’s Board of Directors, effective August 1, 2019. Mr. Grace has been a member of Tonix’s Board of Directors since 2011. “It has...
Jul 25, 2019 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,357,465 to the Company on July 23,...
Jul 18, 2019 04:05 pm ET
Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the closing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public...
Jul 16, 2019 08:30 am ET
Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public...
Jun 13, 2019 07:00 am ET
Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve...
May 30, 2019 08:00 am ET
Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve...
May 28, 2019 04:15 pm ET
Tonix Pharmaceuticals to Present at BIO 2019 International Convention
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix will present at the BIO 2019 International Convention held June 3-6, 2019, in...
May 23, 2019 07:00 am ET
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing small molecules and biologics to treat psychiatric, pain and addiction conditions as well as to improve...
May 22, 2019 04:19 pm ET
Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the first annual Second Chance Digital Impact Recipient Gala being...
May 21, 2019 04:15 pm ET
Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that it will be presenting pharmacokinetic analyses of TNX-102 SL* in a poster at the American Society of Clinical Psychopharmacology (ASCP) 2019 Annual...
May 17, 2019 04:05 pm ET
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced that Donald W. Landry, M.D., Ph.D., is stepping down from the Company’s Board of Directors, effective May 16, 2019. Dr. Landry has served on the Board of Directors of Tonix since...
May 13, 2019 08:00 am ET
Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense, today...
May 08, 2019 07:00 am ET
Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Daniel Goodman, M.D., MBA to its Board of Directors, effective May 6, 2019. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are...
Apr 23, 2019 01:51 pm ET
Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), announced on April 18, 2019 that the Company received a notice of termination, effective April 29, 2019, whereby USAMMDA is exercising its contractual right to terminate...
Apr 22, 2019 07:00 am ET
Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company developing pharmaceutical products to treat psychiatric and pain conditions, and biological products to improve biodefense, today...
Apr 04, 2019 07:30 am ET
Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric and central nervous system conditions, and...
Mar 25, 2019 08:00 am ET
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at two upcoming investor conferences. Details of the Tonix Pharmaceuticals presentations and webcasts are as follows:...
Mar 18, 2019 08:00 am ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Mar 12, 2019 07:30 am ET
Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host investor meetings at the following two investor conferences: Event: 31st Annual ROTH ConferenceDate: March...
Mar 11, 2019 07:00 am ET
Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Mar 08, 2019 08:31 am ET
Thinking about buying stock in Canopy Growth Co., Goldcorp Inc., Seelos Therapeutics Inc., Tonix Pharma Corp., or Trovagene Inc.?
NEW YORK, March 8, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, GG, SEEL, TNXP, and TROV....
Mar 07, 2019 04:15 pm ET
Tonix Pharmaceuticals Announces New European Use Patent for TNX-601
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Mar 01, 2019 05:41 pm ET
Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Mar 01, 2019 04:00 pm ET
Tonix Pharmaceuticals Announces Share Repurchase Program
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that its Board of Directors has approved a share repurchase program pursuant to which the Company may repurchase up to $2 million in value of its outstanding...
Feb 19, 2019 04:30 pm ET
Tonix Pharmaceuticals Announces New Board Member, James Treco
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced the appointment of James Treco to its Board of Directors, effective immediately. Mr. Treco assumes the seat held by Charles Mather, who has stepped down from...
Feb 04, 2019 08:00 am ET
Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at the 21st Annual BIO CEO & Investor Conference on...
Jan 02, 2019 07:00 am ET
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in January 2019. In...
Dec 18, 2018 07:00 am ET
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Dec 11, 2018 04:00 pm ET
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Dec 07, 2018 10:35 am ET
Tonix Pharmaceuticals Prices $15,000,000 Public Offering
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Nov 29, 2018 07:00 am ET
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that it has received the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug...
Nov 27, 2018 07:00 am ET
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense,...
Nov 21, 2018 07:35 am ET
Analysis: Positioning to Benefit within The ONE Group Hospitality, Biofrontera AG Sponsored ADR, Aridis Pharmaceuticals, Universal Logistics, Tonix Pharmaceuticals Holding, and AVROBIO — Research High
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The ONE Group Hospitality, Inc. (NASDAQ:STKS), Biofrontera AG Sponsored...
Nov 09, 2018 07:30 am ET
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve...
Nov 07, 2018 07:00 am ET
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,117,936 to the Company on November 6, 2018. This patent, “Eutectic Formulations...
Nov 06, 2018 07:00 am ET
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) presented a poster at CNS Summit 2018 held November 1-4, 2018, in Boca Raton, Fla.  A poster, entitled “Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind,...
Nov 01, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the 24th Annual BIO-Europe International Partnering Conference on Wednesday,...
Oct 31, 2018 07:00 am ET
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that it plans to start a new Phase 3 trial of Tonmya®* for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019, based on...
Oct 29, 2018 07:00 am ET
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in two posters at CNS Summit 2018 being held November...
Oct 23, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Dawson James Securities 4th Annual Small Cap Growth...
Sep 26, 2018 01:30 pm ET
Tonix Pharmaceuticals to Present at the MicroCap Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the MicroCap Conference being held October 1-2, 2018, in...
Sep 20, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti Company Fall 2018 Investor Conference being...
Sep 07, 2018 07:00 am ET
Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately.  Dr. Olukotun assumes the seat held by Dr. Ernest Mario, who has stepped...
Aug 30, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences in September. Details of the...
Aug 22, 2018 04:01 pm ET
Tonix Pharmaceuticals Announces Director Stepping Down
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors, effective August 21, 2018. Dr. Saks has served on the Board of Directors of Tonix since May...
Aug 21, 2018 07:00 am ET
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health Sys
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) is presenting a poster today at the 2018 Military Health System Research Symposium (MHSRS) in Kissimmee, Fla.  The poster, entitled “Effect of Time Since Trauma on Response to TNX-102 SL*...
Aug 15, 2018 11:46 am ET
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the Phase 3 HONOR study and Phase 2 AtEase Study in a poster, at the 2018 Military Health System Research...
Aug 13, 2018 07:00 am ET
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today...
Jul 27, 2018 08:00 am ET
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that it will stop the Phase 3 HONOR study of Tonmya*(cyclobenzaprine HCl sublingual tablets) in military-related posttraumatic stress disorder (PTSD) due to inadequate...
Jul 16, 2018 07:00 am ET
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational new drug, TNX-102 SL, for the treatment of agitation in...
May 31, 2018 04:30 pm ET
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), presented data from the Phase 2 AtEase study of Tonmya®* (cyclobenzaprine HCl sublingual tablets) for the treatment posttraumatic stress disorder (PTSD). The presentation focused on the...
May 30, 2018 08:00 am ET
Tonix Pharmaceuticals to Present at the 2018 BIO International Convention
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present an overview of the Company, focusing on Tonix’s lead product candidate, Tonmya®*, or...
May 24, 2018 07:00 am ET
Tonix Pharmaceuticals Reports Preliminary Results from a Phase 1 Pivotal Multiple-Dose Bridging Pharmacokinetic (PK) Study of Tonmya® or TNX-102 SL
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced preliminary results from a Phase 1 pivotal multiple-dose bridging pharmacokinetic study of Tonmya®*, or TNX-102 SL, which is required to support the 505(b)(2) NDA submission for...
May 23, 2018 04:05 pm ET
Tonix Pharmaceuticals to Present at the 2018 American Society of Clinical Psychopharmacology
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix, will present at the 2018 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting being held May 29...
May 14, 2018 07:00 am ET
Tonix Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Programs Update
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, today...
May 07, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at the BIO KOREA 2018 International Convention
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense,...
May 01, 2018 07:00 am ET
Tonix Pharmaceuticals Receives IND Clearance by U.S. FDA for TNX-102 SL in Agitation in Alzheimer’s Disease
Agitation in Alzheimer’s Disease, a Potential New Indication for TNX-102 SL, currently in Phase 3 Development as a Treatment for Posttraumatic Stress Disorder (PTSD)
Apr 04, 2018 07:00 am ET
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
First 50 Percent of Participants Enrolled in Phase 3 HONOR Study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of Military-Related PTSD
Apr 03, 2018 07:00 am ET
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Phase 3 HONOR Study Enrollment Continues and Interim Results of the First 50 Percent of Participants Expected in Third Quarter 2018
Mar 26, 2018 04:05 pm ET
Eyenovia Appoints Three Industry Veterans to Board of Directors
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that it...
Mar 21, 2018 04:05 pm ET
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
U.S. Patent Issued Covering the Use of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for treating Posttraumatic Stress Disorder (PTSD)
Mar 13, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium (CHIPS) being held March 15-17, 2018,...
Mar 12, 2018 07:00 am ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
Interim Analysis for Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) inMilitary-Related PTSD Expected in Third Quarter of 2018; Topline Results Expected in Fourth Quarter of 2018
Mar 06, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense through developing potential medical...
Feb 15, 2018 07:00 am ET
Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) today announced the appointment of David L. Grange, a retired U.S. Army Brigadier General, to the Board of Directors. In addition to his military...
Feb 07, 2018 04:30 pm ET
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense through developing potential medical...
Jan 24, 2018 04:30 pm ET
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at Noble Capital Markets’ Fourteenth Annual Investor Conference being held January 29-30, 2018 in Fort Lauderdale.
Jan 23, 2018 07:00 am ET
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Patent Will Provide Intellectual Property Protection until 2030 for Use of Cyclobenzaprine in the Treatment of Posttraumatic Stress Disorder (PTSD)
Jan 09, 2018 07:00 am ET
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, today announced the appointment of Jessica Morris as Chief Operating...
Jan 03, 2018 07:00 am ET
Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will participate in two upcoming conferences...
Dec 12, 2017 07:00 am ET
Nov 30, 2017 07:00 am ET
Tonix Pharmaceuticals to Present at 10th Annual LD Micro Investor Conference
NEW YORK, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company in Phase 3 development of Tonmya®* (cyclobenzaprine HCI sublingual tablets), or TNX-102 SL, a U.S. Food and Drug Administration-designated Breakthrough Therapy for...
Nov 07, 2017 07:00 am ET
Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update
Enrolling Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) in Military-Related PTSD: Interim Analysis Expected 1H18 and Topline Results Expected 2H18
Nov 01, 2017 07:00 am ET
Tonix Pharmaceuticals to Present at 23rd Annual BIO-Europe International Partnering Conference
NEW YORK, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will present at the 23rd  Annual...
Sep 06, 2017 07:00 am ET
Tonix Pharmaceuticals to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public health challenges, announced today that it will present at the Rodman & Renshaw 19th Annual Global Investment Conference being held September 10-12, 2017, in New York, NY....
Aug 29, 2017 04:30 pm ET
Tonix Pharmaceuticals Presented Additional Phase 2 Clinical Results in Military-Related PTSD and Design of Ongoing Phase 3 Trial at the 2017 Military Health System Research Symposium
Phase 2 Study of U.S. FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCI Sublingual Tablets) in PTSD Indicates Early Sleep Quality Improvements Correlate with Later Response to Treatment...
May 30, 2017 04:30 pm ET
Tonix Pharmaceuticals Presented Retrospective Analyses of Treatment Response and Remission to TNX-102 SL in a Phase 2 Military-Related PTSD Study
NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented an oral pipeline presentation on May 30, 2017 entitled “Low-Dose Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response” at the 2017 American Society of Clinical Psychopharmacology Annual Meeting in Miami Beach. The presentation can be found on the Scientific Presentat...
May 22, 2017 04:05 pm ET
Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTS
NEW YORK, May 22, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented a poster on May 20, 2017, entitled “Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response” (Poster No. 3001130) at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry in San Diego. The poster can be found on the Scientific Presentations page on ...
May 11, 2017 07:00 am ET
Tonix Pharmaceuticals to Present PTSD Clinical Data at the Society of Biological Psychiatry 72nd Annual Scientific Convention
NEW YORK, May 11, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, announced it will present additional analyses of data from its Phase 2 study in military-related posttraumatic stress disorder, or PTSD, at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) on May 20, 2017 in San Diego....
Apr 17, 2017 07:00 am ET
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
First Participant Enrolled in Phase 3 HONOR Study of TNX-102 SL in Military-Related PTSD in 1Q2017...
Apr 13, 2017 11:30 am ET
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
NEW YORK, April 13, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (“Tonix”), a company that is developing innovative pharmaceutical products to address public health challenges, today announced that the underwriters of Tonix’s previously announced public offering that initially closed on April 4, 2017, have purchased an additional 270,000 shares of Tonix’s common stock at a price of $4.45 per share, before deducting the underwriting discount, in connection with the exercise in full of their over-allotment option. Tonix has now sold a total of 2,070,000 shares of its com...
Mar 29, 2017 04:07 pm ET
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
NEW YORK, March 29, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (“Tonix”), a company that is developing innovative pharmaceutical products to address public health challenges, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. Tonix intends to use the net proceeds from this offering to support the continued development of TNX-102 SL for the treatment of PTSD, including the HONOR study in military-related PTSD, to further develop other pipeline programs, for working capital and other general corporate purp...
Mar 02, 2017 07:23 am ET
Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, working with researchers from the University of Alberta, a leading Canadian research university, today announced the successful synthesis of a potential smallpox-preventing vaccine. This vaccine candidate, TNX-801, is a live form of horsepox virus (HPXV) that has been demonstrated to have protective vaccine activity in mice. ...
Nov 10, 2016 04:30 pm ET
Tonix Pharmaceuticals Reports Third Quarter 2016 Financial Results
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced financial results for the third quarter ended September 30, 2016....
Nov 10, 2016 07:00 am ET
Tonix Pharmaceuticals to Present New Clinical Results from Retrospective Analysis of Phase 2 AtEase Study in Military-Related PTSD
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), will announce new results today from a retrospective analysis of the data from the AtEase study, a 12-week, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating TNX-102 SL*, 5.6 mg, in military-related PTSD....
Nov 02, 2016 07:00 am ET
Tonix Pharmaceuticals to Present at 22nd Annual BIO-Europe® International Partnering Conference
NEW YORK, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 22nd Annual BIO-Europe International Partnering Conference being held November 7-9, 2016 in Cologne, Germany....
Nov 01, 2016 04:30 pm ET
Tonix Pharmaceuticals to Present Clinical Data at the 2016 Neuroscience Education Institute (NEI) Psychopharmacology Congress
NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX-102 SL* for the treatment of military-related PTSD in a poster at the 2016 NEI Psychopharmacology Congress being held November 3-6, 2016 in Colorado Springs, CO....
Oct 31, 2016 04:30 pm ET
Tonix Pharmaceuticals Completes $5.2 Million Underwritten Public Offering
NEW YORK, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 9,500,000 units, consisting of 9,500,000 shares of common, and warrants to purchase an aggregate of 4,750,000 shares of common stock, at an offering price of $0.55 per unit. The underwriter also purchased additional warrants to acquire 712,500 common shares pursuant to the over-allotment option exercised in part by the underwriter. The warrants have an exercise price of $0.63 per share and are exerci...
Oct 27, 2016 04:32 pm ET
Tonix Pharmaceuticals to Present Clinical Data at CNS Summit 2016
NEW YORK, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present efficacy results of a retrospective analysis of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD in a poster at CNS Summit 2016 being held October 27-30, 2016 in Boca Raton, Florida....
Oct 26, 2016 08:46 am ET
Tonix Pharmaceuticals Prices $5.2 Million Underwritten Public Offering
NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 9,500,000 units, consisting of 9,500,000 shares of common, and warrants to purchase an aggregate of 4,750,000 shares of common stock, at an offering price of $0.55 per unit.  The warrants have an exercise price of $0.63 per share and are exercisable for a period of five years.  Tonix has also granted to the underwriters a 45-day option to acquire an additional 1,425,000 shares of common stock, and warrants to purchase up to...
Oct 25, 2016 05:14 pm ET
Tonix Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Warrants
NEW YORK, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), today announced that it intends to offer shares of its common stock and warrants to purchase common stock in an underwritten public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
Oct 19, 2016 07:00 am ET
Tonix Pharmaceuticals to Host Posttraumatic Stress Disorder (PTSD) Awareness Day
NEW YORK, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced today that it will host an educational event featuring prominent academic physicians to review issues related to understanding and treating PTSD on October 26, 2016 in New York, NY....
Oct 18, 2016 05:47 pm ET
UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
NEW YORK, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Second Annual Dawson James Securities Small Cap Growth Stock Conference being held October 20, 2016 in Jupiter, Florida....
Oct 13, 2016 07:00 am ET
Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
NEW YORK, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Second Annual Dawson James Securities Small Cap Growth Stock Conference being held October 20, 2016 in Jupiter, Florida....
Sep 26, 2016 09:00 am ET
Tonix Pharmaceuticals to Present at 16th Annual Sachs Biotech in Europe Forum
NEW YORK, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the 16th Annual Biotech in Europe Forum being held on September 27-28, 2016 in Basel, Switzerland by Sachs Associates....
Sep 07, 2016 07:39 am ET
Tonix Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investment Conference
NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for posttraumatic stress disorder (PTSD), announced today that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference being held September 11-13, 2016 in New York, NY....
Sep 06, 2016 07:00 am ET
Tonix Pharmaceuticals Reports Topline Results from Phase 3 AFFIRM Study of TNX-102 SL in Fibromyalgia and Provides Corporate Update
Following Completion of AFFIRM, Tonix to Prioritize Resources for Advancing Posttraumatic Stress Disorder (PTSD) Program into Phase 3...
Aug 29, 2016 07:00 am ET
Aug 15, 2016 07:00 am ET
Tonix Pharmaceuticals Presents Poster on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2016 Military Health System Research Symposium
NEW YORK, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present efficacy and safety results of TNX-102 SL (cyclobenzaprine HCl sublingual tablets),  for the treatment of military-related PTSD, in a poster at the 2016 Military Health System Research Symposium being held August 15-18, 2016 in Kissimmee, FL....
Aug 08, 2016 07:00 am ET
Tonix Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Programs Update
First Phase 3 Study of TNX-102 SL in Fibromyalgia to Report Topline Results in September...
Jul 26, 2016 08:00 am ET
Tonix Pharmaceuticals Initiates Second Pivotal Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia
NEW YORK, July 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that the first patient has been randomized in RE-AFFIRM, the second Phase 3 clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets), 2.8 mg, in fibromyalgia....
Jul 12, 2016 04:30 pm ET
Tonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
NEW YORK, July 12, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced that the underwriters of Tonix’s previously announced public offering that initially closed on June 21, 2016, have purchased an additional 750,000 shares of Tonix’s common stock at a price of $2.00 per share, before deducting the underwriting discount, in connection with the exercise in full of their over-allotment option. Tonix has now sold a total of 5,750,000 shares of its common stock in connection with the offering, with total gross proceeds of $11.5 million, before...
Jul 07, 2016 04:05 pm ET
Tonix Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
NEW YORK, July 07, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference being held July 12-13, 2016 in New York, NY....
Jun 21, 2016 12:00 pm ET
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
NEW YORK, June 21, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock.  The shares were sold at the public offering price of $2.00 per share, bringing the aggregate gross proceeds from the offering to $10 million, before deducting underwriting discounts and commissions and other offering expenses.  The financing was led by healthcare focused institutional investors....
Jun 17, 2016 08:00 am ET
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
NEW YORK, June 17, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:00 p.m. ET in New York, NY....
Jun 16, 2016 08:00 am ET
Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
NEW YORK, June 16, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a price of $2.00 per share. Tonix has also granted to the underwriters a 45-day option to acquire an additional 750,000 shares to cover overallotments in connection with the offering....
Jun 15, 2016 04:01 pm ET
Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
NEW YORK, June 15, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering....
Jun 09, 2016 10:30 am ET
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
NEW YORK, June 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), announced that today the company presented results from a retrospective analysis from its Phase 2b BESTFIT clinical study further supporting TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg for the treatment of fibromyalgia. Data were featured in a poster presentation at the European League Against Rheumatism (EULAR) Scientific Congress being held June 8-11, 2016 in Lon...
Jun 03, 2016 07:00 am ET
Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the 2016 BIO International Convention on Tuesday, June 7th, 2016 at 3:15 p.m. PT in San Francisco, CA....
May 31, 2016 07:00 am ET
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annu
Study Successfully Identified Effective and Well-tolerated Dose for Registration StudiesPhase 3 Clinical Program Planned NEW YORK, May 31, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and PTSD, today announced the presentation of positive results from its Phase 2 dose-finding clinical study (AtEase Study) of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD. Data are featured in oral and poster presentations on May 31 and June 1 at the American...
May 26, 2016 08:30 am ET
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
NEW YORK, May 26, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced that it will present positive data from the Phase 2 dose-finding clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD (AtEase Study). Data will be featured in oral and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP, formerly NCDEU) being held May 30 – June 3, 2016 in ...
May 19, 2016 06:00 am ET
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
Conference Call and Webcast Today at 8:00 a.m. ETSuccessfully-executed Dose-finding Study Identified 5.6 mg as the Efficacious and Well-tolerated Dose for Registration StudiesPlan to Meet with the U.S. Food and Drug Administration (FDA) to Finalize Phase 3 Clinical ProgramTopline Data will be Presented at the American Society of Clinical Psychopharmacology Annual Meeting in Scottsdale, Arizona on May 31, 2016 NEW YORK, May 19, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumati...
May 09, 2016 07:00 am ET
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
NEW YORK, May 09, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the first quarter ended March 31, 2016....
May 02, 2016 07:05 am ET
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
- Top-line Results on Track to be Reported 3Q 2016 for Pivotal Study in Flagship Program -...